MREG and neoplasm: Immunodepletion of myeloid populations targeted by anti-GR1 antibody, when conducted at the right timing, augmented cures of host mice that can be attributed to blocking the activity of Mreg associated with responses to tumor treatment by PDT or PDT-generated cancer vaccines.